One HIV Shot, Two Prices: $28,218 a Year in America, $40 in Licensed Countries From 2027. Nine African Nations Planned About 1.37 Million Shots. Their Funders Secured 600,000 Across Every Country They Serve.

Two injections a year, and in one of the two pivotal trials, no infections at all. Lenacapavir, the HIV prevention shot Gilead sells in the US as Yeztugo, produced zero infections among 2,134 cisgender women in PURPOSE 1 and two among 2,179 cisgender men and gender-diverse people in PURPOSE 2. It lists at $14,109 per injection in the US, $28,218 a year, and from 2027 generic makers licensed by Gilead will sell the same molecule for $40 a year in up to 120 countries. Seven hundred and five to one.

Between those prices sits 2026, the year the shot exists but the generics do not. Gilead supplies the Global Fund and PEPFAR at an undisclosed no-profit price, and the two funders secured 600,000 doses for 2026, all of Gilead's capacity for those programs by aidsmap's account. Nine African countries built plans around it, and in July aidsmap reported 191,620 doses delivered, "around 14% of the planned total". Divide by 0.14 and aidsmap's "over a million" sharpens to about 1.37 million shots, 770,000 more than the 600,000 their funders secured across every country they serve: 42 to 45 percent across the rounding band, and a ceiling, since the 600,000 is shared.

One Injection, Two Invoices

In the second quarter of 2026 Yeztugo booked $232 million, against a full-year target reported near $1 billion. Divided at the US list price of $14,109 an injection, which treats every dollar as a list-price American one, the quarter bought at least 16,400 injections, an annual pace near 33,000 person-years, and both figures are floors because net prices run below list.

Turn the invoice over. A billion dollars of Yeztugo revenue, spent at $40 a person, would buy 25 million person-years of the drug. In 2023, 3.5 million people started or continued PrEP worldwide, against a UNAIDS target of 21.2 million for 2025. The industry says the American price funds the research; what happens before $40 arrives is the question.

What 600,000 Doses Buy

A person who starts in 2026 needs a second shot in six months, so 600,000 doses is 300,000 people covered for a year, or 600,000 first shots billing 2027 for the seconds. Either way, the next shot is 2027's problem. The one persistence figure on record is American: Gilead says over 70 percent of Yeztugo users returned for the six-month shot.

South Africa planned 345,000 shots in 2026 and by September 7 its health department counted 55,123 people started, 71 percent of them women: 16 percent of the plan in first shots, and since the second dose falls six months after the first, only those who started before July get theirs inside 2026. Across the nine countries by late July, nearly 66,000 people started on 191,620 delivered doses, 2.9 a person, so the count is stock shipped, not shots in arms.

In South Africa, at least, demand is not the problem. In the rollout's first six weeks, Bhekisisa found 98.5 percent of people offered the choice took the injection over the daily pill, and 28 percent were men, almost three times the pill's share. aidsmap reported one Gauteng client turned away at three clinics in July. NPR found Uganda's batch, nearly 20,000 doses, arrived in February, went out in April, a month late, and skipped Kalangala, which hosted PURPOSE 1, with more stock due in November 2026.

What the Shot Would Cost the World

UNAIDS estimated 1.2 million new infections in 2025, and international HIV financing fell from $8.8 billion in 2024 to $7.3 billion. A year of the $40 drug for that many people, a scale marker, not a coverage plan, since it goes to people without the virus, costs $48 million, 0.66 percent of that envelope; at US list price the same count is $33.9 billion, 4.6 times it.

Cheap is relative. A 2024 Lancet HIV model put the highest cost-effective price per dose at $106.28 in South Africa, $21.15 in Zimbabwe and $16.58 in western Kenya. At $20 a dose, the generic price clears South Africa, squeaks past Zimbabwe and misses western Kenya. At the $64 a year that Contagion Live's IDWeek coverage says PEPFAR arranged for 2026, $32 a dose, only South Africa clears. Gilead has not published its program price and Public Citizen has cited about $100 a year, so if either figure is close, the 2026 price runs 1.6 to 2.5 times the 2027 price in the scarcest year.

The Countries Locked Out

Gilead's licenses cover low- and lower-middle-income countries plus named exceptions, so Brazil, Peru, Mexico and Argentina, which all hosted PURPOSE trials, sit outside as upper-middle-income. Brazil's health minister, Alexandre Padilha, said talks had stalled because Gilead asked 10 times the price paid by Indonesia and Thailand; Doctors Without Borders asked for $40 a year in every low- and middle-income country and, by its account, the AIDS 2026 conference in Rio closed with Gilead's terms unchanged.

Tiering has a defense. A company that charges Brazil what it charges Zambia will not charge Zambia $40 for long. Against that stands the calendar. Every year of the gap leaves four trial countries outside the licenses, and the funders' 3 million people through 2028 is cumulative against the 21.2 million UNAIDS wanted covered in 2025 alone: three years of this program against one year of that target, and still 14 percent of it.

What You Can Do

In the United States, if you take daily PrEP and miss doses, ask a clinician about the injection and check your plan first, because the preventive-care rule that makes PrEP free predates this drug and coverage still varies by insurer and benefit manager. Where the shot is out of stock, daily oral PrEP remains the established option, and how to bridge with it is a question for the clinic that started you. Funders should secure the second shot before programs recruit for the first.

Limitations

Every figure comes from search summaries, not primary pages, and the 1.37 million is our back-calculation from aidsmap's rounded 14% of doses delivered, not given, so the band is 1.32 to 1.42 million. We did not approach Gilead, the Global Fund, PEPFAR or any ministry of health.

The Strongest Case Against This Analysis

Dividing a list price by a generic price is theater when almost nobody in America pays $28,218, insurers pay undisclosed net prices, and the revenue funds the pipeline. Generic deals three months after approval, royalty-free licenses to six manufacturers across 120 countries, a no-profit supply to 3 million people and a $40 generic from 2027 are unusually fast, and no factory conjures 1.37 million doses in a launch year. Most of that is fair; the 705 to one compares two public numbers, not what any insurer paid. What the defense leaves unanswered is timing: four trial countries will not get $40 generics while the licenses exclude them, every reported 2026 price sits above the 2027 price, and the district Uganda skipped in April waits for stock due in November 2026.

The Bottom Line

705 to one, and 45 percent at best. Someone who took a first shot in Gauteng in July 2026 needs the second by January 2027; someone at a trial site in Brazil needs a license their country is outside, or the tenfold price Padilha alleges. The molecule is the same in every syringe. Only the invoice changes.

Related

• 240 Million Hepatitis B Patients Can’t Afford $2.2 Million Gene Therapy. An IV Drip Just Silenced Their Virus for 17 Months.
• Two Generic Drugs That Cost $1 a Day Just Showed the Biggest Survival Benefit in ALS History
• Medicare's GLP-1 Bridge Costs $245 a Month. The Break-Even Price Is $150. Nobody Changed the Number.